Insider Selling: Pulmonx Co. (NASDAQ:LUNG) CFO Sells 14,384 Shares of Stock

Pulmonx Co. (NASDAQ:LUNG) CFO Mehul Joshi sold 14,384 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.12, for a total transaction of $102,414.08. Following the transaction, the chief financial officer now owns 113,986 shares in the company, valued at approximately $811,580.32. The trade was a 11.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Pulmonx Stock Down 5.5 %

Shares of NASDAQ:LUNG opened at $8.19 on Thursday. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. Pulmonx Co. has a 52-week low of $5.46 and a 52-week high of $10.01. The company has a 50 day moving average of $6.93 and a two-hundred day moving average of $6.93. The company has a market capitalization of $325.93 million, a price-to-earnings ratio of -5.69 and a beta of 0.50.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings data on Wednesday, February 19th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.12. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. The company had revenue of $23.77 million during the quarter, compared to the consensus estimate of $22.29 million. As a group, analysts forecast that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.

Institutional Trading of Pulmonx

A number of hedge funds have recently made changes to their positions in LUNG. 272 Capital LP acquired a new stake in shares of Pulmonx during the third quarter worth approximately $25,000. BNP Paribas Financial Markets acquired a new stake in shares of Pulmonx during the fourth quarter worth approximately $43,000. R Squared Ltd acquired a new stake in shares of Pulmonx during the fourth quarter worth approximately $46,000. ProShare Advisors LLC acquired a new stake in shares of Pulmonx during the fourth quarter worth approximately $72,000. Finally, Stifel Financial Corp acquired a new stake in shares of Pulmonx during the fourth quarter worth approximately $81,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Citigroup reissued a “neutral” rating and set a $7.50 target price (down previously from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th. Wells Fargo & Company dropped their target price on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.75.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.